Clinical Trial Finder

Inclusion Criteria:

• - Each patient must meet the following criteria: 1.

Provide signed, written informed consent prior to the initiation of any study-specific procedures. 2. Have histologically or cytologically confirmed diagnosis of advanced solid tumor cancer (excluding lymphomas) for which there is no further standard therapy or when standard therapy is contraindicated. Patients with HGG must have shown unequivocal evidence for recurrence or progression by MRI scan or must have histologically proven tumor recurrence. 3. Patients with HGG: Have previously received radiotherapy and temozolomide. 4. For patients with HGG and receiving glucocorticoid therapy, must be on stable or decreasing equivalent daily dose of glucocorticoids for 2 weeks (14 days) prior to dose assignment. 5. Have measurable or non-measurable disease per RECIST 1.1 criteria for solid tumors and RANO criteria for HGG. 6. Are males or females aged ≥ 18 years. 7. Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0

• - 2.

8. Have acceptable liver function defined as:

• - Total serum bilirubin ≤ 1.5 × upper limit of normal for the study site (ULN) (in patients with known Gilbert Syndrome, total bilirubin ≤ 3 × ULN, with direct bilirubin ≤ 1.5 × ULN) - Aspartate Transaminase (AST), Serum Glutamic Oxaloacetic Transaminase (SGOT), Alanine Transaminase (ALT), Serum Glutamic-Pyruvic Transamine (SGPT) ≤ 3 × ULN (if liver metastases are present, then ≤ 5 × ULN is allowed) - Serum albumin ≥ 3 g/dL.

9. Have acceptable renal function defined as: Serum creatinine ≤ 1.5 × ULN, OR calculated creatinine clearance ≥ 45 mL/min for patients with creatinine levels above 1.5 mg/dL. 10. Have acceptable bone marrow function defined as:

• - Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3.

• - Platelet count ≥ 100,000 cells/mm3.

• - Hemoglobin > 9.0 g/dL.

11. Have acceptable coagulation parameters defined as:

• - International normalized ratio (INR) ≤ 2 × ULN.

• - Activated partial thromboplastin time (aPTT) within normal limits.

12. Have a negative serum pregnancy test result at screening (for females of child bearing potential (FCBP); not applicable to patients who are unable to become pregnant, including those with tubal ligation, bilateral oophorectomy and/or hysterectomy, post-menopausal is defined as > 12 months since last menstrual cycle) 13. FCBP and male patients whose sexual partner(s) are FCBP must agree to abstain from heterosexual activity or use a double barrier method of contraception (e.g., condom and occlusive cap with spermicide) or highly effective contraception (intrauterine device or system, established hormonal contraceptive methods on a stable dose from the time of the last menstrual cycle, or vasectomized partner with confirmed azoospermia) from the time of study entry to 1 month after the last day of treatment.

Exclusion Criteria:

• - Patients must not meet any of the following criteria: 1.

Have a concurrent malignancy or have had another malignancy within 1 year prior to initiation of screening (with the exception of adequately treated basal or squamous cell carcinoma, melanoma in situ, early-stage prostate cancer (T1a-cN0M0), ductal carcinoma in situ of the breast or cervical carcinoma in situ) 2. Patients with solid tumors: Have received anticancer therapies, including radiation therapy, cytotoxic agents, targeted agents or endocrine therapy within 2 weeks prior to dose assignment. 3. Patients with HGG: Have received anticancer therapies including: radiation therapy to current site of disease within 12 weeks of dose assignment, targeted agent therapy within 2 weeks of dose assignment, nitrosoureas within 6 weeks of dose assignment, procarbazine within 3 weeks of dose assignment, or other cytotoxic agents within 4 weeks of dose assignment. 4. Have not recovered from toxicity of prior therapy defined as a return to < grade 1 at the time of dose assignment, graded according to CTCAE v4.03 (excluding alopecia, neuropathy, and lymphopenia) 5. Have received prior treatment with any investigational drug within 4 weeks prior to dose assignment. 6. Have had major surgery other than a minor outpatient procedure within 4 weeks prior to dose assignment or have not recovered from major side effects of the surgery if more than 4 weeks have elapsed since surgery. 7. Have a history of cardiac dysfunction including:

• - Myocardial infarction within 6 months prior to initiation of screening.

• - History of documented congestive heart failure (New York Heart Association functional classification III-IV) within 6 months prior to initiation of screening.

• - Active cardiomyopathy.

• - ECG with correctd QT interval (QTc) >450 msec in males or >470 msec in females at screening.

8. Have a known history of HIV seropositivity. 9. Are pregnant or nursing (lactating), where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum human chorionic gonadotropin (hCG) laboratory test. 10. Have symptomatic brain metastases or leptomeningeal disease. 11. Have active (acute or chronic) or uncontrolled severe infections. 12. Have active poor wound healing (delayed healing, wound infection or fistula) 13. Have poorly controlled hypertension defined as blood pressure >160/90 on at least 2 repeated determinations on separate days within 2 weeks (14 days) prior to initiation of screening. 14. Have evidence of active clinically significant bleed (e.g., gastrointestinal bleed, hemoptysis, or gross hematuria) at screening. 15. Have other concurrent severe and/or uncontrolled medical condition that would, in the site Investigator's judgment contraindicate the patient's participation in the clinical study

This is a first in man study of BXQ-350, a novel anti-neoplastic therapeutic agent composed of two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together forming stable SapC-DOPS nanovesicles (clinical formulation BXQ-350), the agent exhibits the propensity to enter the body and brain, target cells in the tumor mass, and induce cell death. The study is divided into 3 parts: 1. Dose Escalation Scheme Sequential cohorts of adult patients with advanced solid tumors and recurrent high-grade gliomas will be treated with escalating doses of BXQ-350 until the MTD is established, or in the absence of a MAD, the highest planned DL. 2. During Part 2, patients with advanced solid tumors and recurrent high-grade gliomas will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at the highest planned DL, if the MAD is not reached. 3. During Part 3, patients with either ependymoma, GI tumors , or advanced solid tumors other than HGG, will be enrolled and administered BXQ-350 at the 2.4 mg/kg dose level.

Arms

Experimental: Rising dose; safety and tolerance

Sequential cohorts of patients with advanced solid tumors and recurrent high-grade gliomas will be be treated with escalating doses of BXQ-350 until the MTD is established, or in the absence of a MAD, the highest planned DL is reached.

Experimental: Solid tumor patients

Cohort of patients with advanced solid tumors administered BXQ-350 at the MTD determined in Part 1 or at the highest planned DL if the MAD is not reached.

Experimental: Glioblastoma Multiforme patients

Cohort of patients with recurrent high-grade gliomas administered BXQ-350 at the MTD determined in Part 1 or at the highest planned DL if the MAD is not reached.

Experimental: Gastrointestinal tumor patients

Cohort of patients with Gastrointestinal tumors as defined in the protocol and administered BXQ-350 at the 2.4 mg/kg dose level.

Experimental: Ependymoma tumor patients

Cohort of patients with ependymoma administered BXQ-350 at the 2.4 mg/kg dose level.

Experimental: Solid tumor patients other than HGG

Cohort of patients with advanced solid tumors other than HGG administered BXQ-350 at the 2.4 mg/kg dose level.

Interventions

Drug: - BXQ-350

BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).